FOLH1 and metastatic prostate carcinoma: Another interesting setting is an ongoing randomized multicenter phase II trial investigating the efficacy of two cycles of 177Lu-PSMA-617 upfront after the initiation of castration, followed by docetaxel chemotherapy in hormone naïve metastatic prostate cancer patients (Table 1, NCT04343885).